ATE401082T1 - Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen - Google Patents

Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen

Info

Publication number
ATE401082T1
ATE401082T1 AT02751784T AT02751784T ATE401082T1 AT E401082 T1 ATE401082 T1 AT E401082T1 AT 02751784 T AT02751784 T AT 02751784T AT 02751784 T AT02751784 T AT 02751784T AT E401082 T1 ATE401082 T1 AT E401082T1
Authority
AT
Austria
Prior art keywords
drug
components
prevention
treatment
medical composition
Prior art date
Application number
AT02751784T
Other languages
English (en)
Inventor
Yoshinori Toshima
Asako Hitomi
Shin-Ichi Satoh
Ichiro Ikegaki
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Application granted granted Critical
Publication of ATE401082T1 publication Critical patent/ATE401082T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02751784T 2001-09-11 2002-07-30 Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen ATE401082T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001274846 2001-09-11

Publications (1)

Publication Number Publication Date
ATE401082T1 true ATE401082T1 (de) 2008-08-15

Family

ID=19099815

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751784T ATE401082T1 (de) 2001-09-11 2002-07-30 Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen

Country Status (6)

Country Link
US (1) US20040242565A1 (de)
EP (1) EP1426051B1 (de)
JP (1) JP4194095B2 (de)
AT (1) ATE401082T1 (de)
DE (1) DE60227679D1 (de)
WO (1) WO2003024457A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097583A1 (en) * 2002-02-14 2004-05-20 Hans-Jochen Lang Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders
ATE520417T1 (de) * 2002-05-17 2011-09-15 Novartis Pharma Gmbh Pharmazeutische zusammensetzung enthaltend einen renin inhibitor, einen kalziumkanalblocker und ein diuretikum
US20040168951A1 (en) * 2003-02-27 2004-09-02 Mackie Robert W. Method and system for self administration of medications
US20040266755A1 (en) * 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
WO2005073218A1 (ja) * 2004-01-29 2005-08-11 Asahi Kasei Pharma Corporation バイパス術に伴う血管攣縮治療剤
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
US20080175831A1 (en) * 2006-12-21 2008-07-24 Macknik Stephen L Neuroprotection by blood flow stabilization
CA2701620C (en) * 2007-10-05 2014-12-09 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
WO2009046338A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
US20110190270A1 (en) * 2008-01-31 2011-08-04 Monash University Methods of treating thromboembolic disorders
FR2927538B1 (fr) * 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
ES2330404B1 (es) * 2008-05-19 2010-09-22 Universidad De Barcelona Solucion acuosa para la preservacion de tejidos y organos.
KR20160094345A (ko) * 2015-01-30 2016-08-09 고려대학교 산학협력단 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583287D1 (de) * 1984-12-27 1991-07-25 Asahi Chemical Ind Substituierte isochinolinsulfonyl-verbindungen.
AU4246793A (en) * 1992-05-13 1993-12-13 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
EP0810862A2 (de) * 1995-02-22 1997-12-10 Takeda Chemical Industries, Ltd. Verwendung von vinylcarbonsaurederivaten zur behandlung oder vorbeugung von transienten ischamischen zustanden
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
WO1997028130A1 (fr) * 1996-02-02 1997-08-07 Nippon Shinyaku Co., Ltd. Derives de l'isoquinoline et medicaments associes
JPH107590A (ja) * 1996-06-24 1998-01-13 Chugai Pharmaceut Co Ltd 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤
CA2415826A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP2002226374A (ja) * 2001-01-31 2002-08-14 Asahi Kasei Corp 狭心症治療用組成物

Also Published As

Publication number Publication date
EP1426051B1 (de) 2008-07-16
WO2003024457A1 (fr) 2003-03-27
EP1426051A1 (de) 2004-06-09
DE60227679D1 (de) 2008-08-28
JPWO2003024457A1 (ja) 2004-12-24
EP1426051A4 (de) 2005-06-15
JP4194095B2 (ja) 2008-12-10
US20040242565A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
ATE401082T1 (de) Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen
CY1120591T1 (el) Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου
DE60234052D1 (de) Vorbeugung und behandlung von oxidativer-stress-erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
RU99115750A (ru) Новые соединения с анальгезирующим действием
DE69912808D1 (de) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
DE60325074D1 (de) Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
EA200601281A1 (ru) Азабензофуранзамещенные тиомочевины; ингибиторы репликации вирусов
DK499385A (da) Piperazinforbindelser
DE602004020685D1 (de) Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
DE60137442D1 (de) 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
ATE284684T1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
DE60123528D1 (de) Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit
ZA891769B (en) Heterocyclic compounds
ATE220065T1 (de) Benzopyranderivate und ihre verwendung zur behandlung von herzkrankheiten
ATE511395T1 (de) Mittel zur behandlung von glomerulopathie
ATE431148T1 (de) Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme
CA2270026A1 (en) Substituted bicyclic derivatives for treating central nervous system disorders
SE9302334D0 (sv) New compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties